Infectious Complications of Trans-rectal Ultrasound Guided Biopsy of the Prostate: A Single Institution Experience
CUA Online Library. Kovac E. 06/22/13; 31438; UP-59
Disclosure(s): No corporate relationships to disclose.
CLICK HERE TO LOGIN
REGULAR CONTENT
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Rate & Comment (0)
Infectious Complications of Trans-Rectal Ultrasound Guided Biopsy of the Prostate: a Single Institution Experience
Evan Kovac MD CM, Emilie Baillargeon, Talal Al-Qaoud MD, Giovanni Artho, and Armen Aprikian MD FRCSC
Department of Urology and Radiology, Montreal General Hospital, Montreal, Quebec, Canada
Introduction and Objectives:
Trans-rectal ultrasound (TRUS) guided biopsy of the prostate is a commonly performed procedure to confirm the diagnosis of adenocarcinoma. Antibiotic prophylaxis with a fluoroquinolone is recommended to prevent the seeding of rectal flora into the urinary tract. However, in recent years infectious complications of the procedure are a growing concern, owing to the emergence of fluoroquinolone resistant bacteria. Our Objective is to evaluate the incidence of fluoroquinolone-resistant bacteremia after TRUS-guided biopsy of the prostate in a tertiary care centre.
Methods:
We retrospectively reviewed all TRUS-guided biopsies of the prostate from January 1st to December 31st, 2010 at a single tertiary care hospital radiology department. A standard 3-day course of oral Ciprofloxacin prophylaxis was used for all patients, beginning 1 day prior to the biopsy. A systematic chart review was conducted to identify patients that presented to our centre within 30 days of biopsy and their respective culture results. In addition, each patient was contacted by phone and administered a questionnaire to determine whether the patient presented post-biopsy to a hospital other than ours.
Results:
Of the 207 patients who underwent TRUS biopsy, 133 (65%) were included in the study. We identified 2 patients with fluoroquinolone-resistant bacteremia (1.5%) and another 3 with a positive urine culture (2.3%). 1 patient developed C-difficile associated diarrhea (0.8%). There were no mortalities and the average hospital stay was 2.4 days.
Conclusions:
Our retrospective review identified patients presenting with fluoroquinolone-resistant bacteremia and/or positive urine cultures post-TRUS guided biopsy of the prostate. Using a 3-day course of fluoroquinolone prophylaxis, we found that our infectious complication rate is similar to those previously published. It is possible that this rate would be slightly different had we been able to contact all patients undergoing biopsy.
Evan Kovac MD CM, Emilie Baillargeon, Talal Al-Qaoud MD, Giovanni Artho, and Armen Aprikian MD FRCSC
Department of Urology and Radiology, Montreal General Hospital, Montreal, Quebec, Canada
Introduction and Objectives:
Trans-rectal ultrasound (TRUS) guided biopsy of the prostate is a commonly performed procedure to confirm the diagnosis of adenocarcinoma. Antibiotic prophylaxis with a fluoroquinolone is recommended to prevent the seeding of rectal flora into the urinary tract. However, in recent years infectious complications of the procedure are a growing concern, owing to the emergence of fluoroquinolone resistant bacteria. Our Objective is to evaluate the incidence of fluoroquinolone-resistant bacteremia after TRUS-guided biopsy of the prostate in a tertiary care centre.
Methods:
We retrospectively reviewed all TRUS-guided biopsies of the prostate from January 1st to December 31st, 2010 at a single tertiary care hospital radiology department. A standard 3-day course of oral Ciprofloxacin prophylaxis was used for all patients, beginning 1 day prior to the biopsy. A systematic chart review was conducted to identify patients that presented to our centre within 30 days of biopsy and their respective culture results. In addition, each patient was contacted by phone and administered a questionnaire to determine whether the patient presented post-biopsy to a hospital other than ours.
Results:
Of the 207 patients who underwent TRUS biopsy, 133 (65%) were included in the study. We identified 2 patients with fluoroquinolone-resistant bacteremia (1.5%) and another 3 with a positive urine culture (2.3%). 1 patient developed C-difficile associated diarrhea (0.8%). There were no mortalities and the average hospital stay was 2.4 days.
Conclusions:
Our retrospective review identified patients presenting with fluoroquinolone-resistant bacteremia and/or positive urine cultures post-TRUS guided biopsy of the prostate. Using a 3-day course of fluoroquinolone prophylaxis, we found that our infectious complication rate is similar to those previously published. It is possible that this rate would be slightly different had we been able to contact all patients undergoing biopsy.
Infectious Complications of Trans-Rectal Ultrasound Guided Biopsy of the Prostate: a Single Institution Experience
Evan Kovac MD CM, Emilie Baillargeon, Talal Al-Qaoud MD, Giovanni Artho, and Armen Aprikian MD FRCSC
Department of Urology and Radiology, Montreal General Hospital, Montreal, Quebec, Canada
Introduction and Objectives:
Trans-rectal ultrasound (TRUS) guided biopsy of the prostate is a commonly performed procedure to confirm the diagnosis of adenocarcinoma. Antibiotic prophylaxis with a fluoroquinolone is recommended to prevent the seeding of rectal flora into the urinary tract. However, in recent years infectious complications of the procedure are a growing concern, owing to the emergence of fluoroquinolone resistant bacteria. Our Objective is to evaluate the incidence of fluoroquinolone-resistant bacteremia after TRUS-guided biopsy of the prostate in a tertiary care centre.
Methods:
We retrospectively reviewed all TRUS-guided biopsies of the prostate from January 1st to December 31st, 2010 at a single tertiary care hospital radiology department. A standard 3-day course of oral Ciprofloxacin prophylaxis was used for all patients, beginning 1 day prior to the biopsy. A systematic chart review was conducted to identify patients that presented to our centre within 30 days of biopsy and their respective culture results. In addition, each patient was contacted by phone and administered a questionnaire to determine whether the patient presented post-biopsy to a hospital other than ours.
Results:
Of the 207 patients who underwent TRUS biopsy, 133 (65%) were included in the study. We identified 2 patients with fluoroquinolone-resistant bacteremia (1.5%) and another 3 with a positive urine culture (2.3%). 1 patient developed C-difficile associated diarrhea (0.8%). There were no mortalities and the average hospital stay was 2.4 days.
Conclusions:
Our retrospective review identified patients presenting with fluoroquinolone-resistant bacteremia and/or positive urine cultures post-TRUS guided biopsy of the prostate. Using a 3-day course of fluoroquinolone prophylaxis, we found that our infectious complication rate is similar to those previously published. It is possible that this rate would be slightly different had we been able to contact all patients undergoing biopsy.
Evan Kovac MD CM, Emilie Baillargeon, Talal Al-Qaoud MD, Giovanni Artho, and Armen Aprikian MD FRCSC
Department of Urology and Radiology, Montreal General Hospital, Montreal, Quebec, Canada
Introduction and Objectives:
Trans-rectal ultrasound (TRUS) guided biopsy of the prostate is a commonly performed procedure to confirm the diagnosis of adenocarcinoma. Antibiotic prophylaxis with a fluoroquinolone is recommended to prevent the seeding of rectal flora into the urinary tract. However, in recent years infectious complications of the procedure are a growing concern, owing to the emergence of fluoroquinolone resistant bacteria. Our Objective is to evaluate the incidence of fluoroquinolone-resistant bacteremia after TRUS-guided biopsy of the prostate in a tertiary care centre.
Methods:
We retrospectively reviewed all TRUS-guided biopsies of the prostate from January 1st to December 31st, 2010 at a single tertiary care hospital radiology department. A standard 3-day course of oral Ciprofloxacin prophylaxis was used for all patients, beginning 1 day prior to the biopsy. A systematic chart review was conducted to identify patients that presented to our centre within 30 days of biopsy and their respective culture results. In addition, each patient was contacted by phone and administered a questionnaire to determine whether the patient presented post-biopsy to a hospital other than ours.
Results:
Of the 207 patients who underwent TRUS biopsy, 133 (65%) were included in the study. We identified 2 patients with fluoroquinolone-resistant bacteremia (1.5%) and another 3 with a positive urine culture (2.3%). 1 patient developed C-difficile associated diarrhea (0.8%). There were no mortalities and the average hospital stay was 2.4 days.
Conclusions:
Our retrospective review identified patients presenting with fluoroquinolone-resistant bacteremia and/or positive urine cultures post-TRUS guided biopsy of the prostate. Using a 3-day course of fluoroquinolone prophylaxis, we found that our infectious complication rate is similar to those previously published. It is possible that this rate would be slightly different had we been able to contact all patients undergoing biopsy.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}